News & Events
Neuro-MSX Transcranial Magnetic Stimulator Authorized by Health Canada Jan, 8, 2023
Health Canada authorized Neuro-MSX Transcranial Magnetic Stimulator for importation and sales in Canada.
Neuronix strives to make transcranial magnetic stimulation (TMS) treatment more affordable and available to all patients who need it, offers lower capital and operating costs of the Neuro-TMS, as well as leasing and financing options.
Neuronix partners with Priority Leasing to finance medical equipment Jan, 3, 2023
Priority Leasing Inc. and Neuronix Inc. announce their partnership to provide financing for medical devices and veterinary diagnostics equipment offered by Neuronix – in Canada and the US.
ANG-06 Multigas Analyzer authorized by Health Canada Dec, 1, 2022
Neuronix is very pleased to announce that Health Canada authorized AMG-06 Multigas Analyzer under the Interim Order Respecting the Importation and Sale of Medical Devices for Use in Relation to COVID-19 – Authorization Reference Number: 334600.
Administering volatile anesthetic agents, such as Sevoflurane, Isoflurane, Desflurane, requires precise control of gas concentration.
Delivery of inhaled volatile agents requires a bedside gas monitoring to provide information on drug dosing.
In particular, COVID-19 patients require delicate therapy, and it is necessary to dose the inhalation anesthetic very precisely.
Bedside end-tidal gas monitoring (correlate of cerebral concentration) can be used to ensure gas delivery, assess concentration of drug needed to achieve a specific clinical sedation endpoint, re-breathing of carbon dioxide and device obstruction.
AMG-06 Multigas Analyzer is intended for continuous non-invasive sidestream monitoring of СО2, isoflurane (ISO), sevoflurane (SEV), desflurane (DES) concentration in inspired (FiCO2, FiDES, FiISO, FiSEV) and expired (EtCO2, EtDES, EtISO, EtSEV) gases without automatic identification of anesthetic, and also for determining patient’s respiration rate (RSP) and apnea, MAC (Minimum Alveolar Concentration)* index, and measuring atmospheric pressure under the conditions of Operating Rooms, ICUs, and wards when providing anesthetic support.
The instrument is used in combination with Sedana Medical Sedaconda® ACD (Anesthetic Conserving Device) vaporizer of volatile anesthetics, with particular application in intensive care units (ICU).
*) The Minimum Alveolar Concentration (MAC) of an inhaled anesthetic is the alveolar (or end-expiratory) concentration at which 50% of patients will not show a motor response to a standardized surgical incision.
Inhalational Sedation in Clinical Practice Workshop at CCCF 2022 Dec, 1, 2022
Proudly hosted during Critical Care Canada Forum 2022, was clinical workshop, Inhalational Sedation in Clinical Practice.
The Workshop was held on 24 December 2022 at Sheraton Centre Toronto Hotel.
The Workshop participants learned why using inhalational anesthetics in critical care, and how to do it.
Presenting at the workshop were leading scientist and clinicians from Sunnybrook Research Institute, Western University, London Health Sciences Centre, Sunnybrook Health Sciences Centre:
· Dr. Angela Jerath, MSc FRCPC, FANZCA, MD, BSc
· Marat Slessarev, PhD, FRCPC
· Julie Nardi RRT, MSc QIPS
· Beth Linseman, RN, BScN, CNCC(C)
The topics discussed included:
· An overview of the use of inhaled anesthetics in ICU – volatile agents (Isoflurane, Sevoflurane, Desflurane), advantages of inhaled sedation vs IV sedation for patient outcomes and economics, exhaled anesthetic gas scavenging, end-tide minimal alveolar concentration (MAC) index monitoring and its importance.
· The SAVE-ICU Multi-Centre trial – in patients with respiratory failure on mechanical ventilation.
· Equipment and delivery of inhalational sedation in the ICU – set up (volatile agent delivery system, agent vaporizer, gas monitor), setting up in the ICU, EEG bed-side monitoring.
The presenters answered numerous questions from the audience.
Inhalational (inhalative) sedation is administered with vaporized volatile anesthetics delivered through the breathing circuit to the patient’s lungs while the patient is on mechanical ventilation.
Inhalational (inhalative) sedation has advantages over intravenous medications. It provides excellent controllability compared to intravenous (IV) sedation with propofol, midazolam, etc., and a low metabolic rate.
It may be a method of choice for sedation in patients with heart, liver, and kidney problems.
Volatile anesthetics ensure controlled use of a sedative and minimize the risk of developing such reactions as prolonged awakening, delirium, impaired cognitive functions after awakening. They may be also suitable in cases when intravenous sedation is contraindicated due to intolerance to intravenous drugs.
Application of inhalative sedation in COVID-19 patients was particularly shown by Canadian researchers and clinicians lead by Dr. Angela Jerath, MSC FRCPC FANZCA MD BSC at Sunnybrook Health Science Centre: Sunnybrook researchers are trialing an alternative method of sedation for critically ill COVID-19 patients. http://health.sunnybrook.ca/research/practice-change-icu-sedative-pandemic/
Intensive Care Ventilators Zisline MV200 and MV300 authorized by Health Canada Jun, 20, 2021
Neuronix is very pleased to announce that Health Canada authorized Intensive Care Ventilators Zisline MV200 and MV300 under the Interim Order No. 2 Respecting the Importation and Sale of Medical Devices for Use in Relation to COVID-19 – Authorization Reference Number: 326828, Issue Date: 2021-05-19.
New investments to support research and science across Canada Mar, 3, 2021
The Prime Minister, Justin Trudeau, today announced an investment to support more than 100 research projects and almost 1,000 researchers across the country.
According to the Announcement, this investment of more than C$518 million will ensure these researchers have the facilities and tools they need, and will fund projects that help us beat the pandemic and build a more resilient Canada.
World Health Organization: One in four people projected to have hearing problems by 2050 Mar, 2, 2021
The first-ever World Report on Hearing, released by the World Health Organization (WHO), projects that nearly 2.5 billion people worldwide ─ or 1 in 4 ─ will have some degree of hearing loss by 2050.
Clinical Evidence of COVID-19 Neurology and Importance of EEG Feb, 3, 2021
The recent clinical evidence shows that COVID-19 negatively affects the functioning of the central nervous system. Moreover, the degree of influence depends on the severity of the course of the disease. In critically ill patients, who have been in intensive care for a long time, even severe damage to the central nervous system is observed up to the appearance of non-convulsive epileptic seizures. The EEG method allows monitoring the state of the central nervous system of such patients and timely applying the necessary treatment methods in order to prevent severe consequences of the disease.
The Emerging Spectrum of COVID-19 Neurology Jul, 19, 2020
In the recently published in the Brain article, The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings, the authors, Ross W Paterson and colleagues, presented preliminary clinical data indicating that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with neurological and neuropsychiatric illness.